Your email client cannot read this email.

To view it online, please go here:

http://www.sgurunews.com/emailmarketer/display.phpM596&C=c7c822f09eefcb0dac0453b7afd60b76&S57&L=3&N88 Having trouble reading this email View it in your browser.

a Vicor Technologies, Inc.

[vcrt-midday-MEDIUM] VCRT Continues its Climb – Now Up 105% Since our Shareholder Vision Video Last Monday Big Week Last Week for VCRT as it Moves Upward 88% from Monday Low to Friday Close – now up 105% and rising! Monday saw a low of $0.085.

Today – so far – at: $0.175 See the video here:

Shareholder Vision Releases New Video Interview with David Fater of Vicor Technologies, Inc.

To view the video interview, please visit:

http://www.sgurunews.com/emailmarketer/link.phpM596&N57&L03&F=T June 21, 2011 Dallas, Texas: John Pentony, Publisher of ShareholderVision.com, announced today that Shareholder Vision has released a new video interview featuring David Fater, President and Chief Executive Officer of Vicor Technologies, Inc. (OTCBB: VCRT). The interview was recorded recently in Boca Raton, Florida, the headquarters for Vicor Technologies, Inc. Shareholder Vision presents an exceptional look at an outstanding company, a CEO with world class experience in his field, and a bio-tech company that is now capitalizing on over a decade of patented work.

Vicor Technologies is a biotechnology company focused on the commercialization of its PD2i Analyzer, an innovative, non-invasive diagnostic employing its patented, proprietary PD2i nonlinear algorithm.

Physician use of the PD2i Analyzer is supported by an expanding body of literature documenting the PD2i nonlinear algorithm as a metric for risk stratifying specific target populations for future pathological events, including diabetics for the presence of diabetic autonomic neuropathy (DAN), cardiovascular disease patients for death resulting from arrhythmia or congestive heart failure, and trauma victims for imminent death absent immediate lifesaving intervention. Vicor is actively transforming itself from a development-stage biotechnology company into a fully-realized commercial venture with a national sales force and international distribution. Physicians are using Vicors PD2i Analyzer to identify autonomic nervous system, also known as diabetic autonomic neuropathy (DAN), in their patients with diabetes, and to identify those among their patients with cardiovascular disease at risk for death resulting from arrhythmia or congestive heart failure. Current procedural terminology (CPT) codes enable physicians using the PD2i Analyzer as a measure of heart rate variability to be reimbursed by insurance carriers, creating a recurring source of revenue from test analysis for Vicor. In April, Vicor received 510(k) marketing clearance from the U.S. Food and Drug Administration for its PD2i Analyzer to be used as a measure of heart rate variability at rest, and in response to controlled exercise and paced respiration (Ewing Maneuvers) in patients specifically undergoing cardiovascular disease testing. Sixty published manuscripts of studies involving the use of Vicors PD2i nonlinear algorithm attest to its ability to identify and predict a wide variety of medical disorders and conditions.

To view the video interview, please visit:

http://www.sgurunews.com/emailmarketer/link.phpM596&N57&L03&F=T StockGuru`s Profile for Vicor Technologies, Inc.

This is the condensed version – Full StockGuru Profile Found Here:

http://www.sgurunews.com/emailmarketer/link.phpM596&N57&L69&F=T Vicor Technologies, Inc. (OTCBB: VCRT) is a medical diagnostics company focused on commercializing noninvasive diagnostic technology products based on its patented, proprietary point correlation dimension algorithm the PD2i Algorithm and software.

With the second FDA approval under its belt in April, Vicor is fully in the process of transforming itself into a commercial company with a national sales force and international reach.

The Company has all of the regulatory approvals in place already with regards to PD2i to generate substantial revenues.

FDA Approval of PD2i Analyzer for BOTH Heart Rate Variability and Cardiovascular Disease Testing Vicors PD2i Analyzer has FDA 510(k) marketing clearance to both:

Measure heart rate variability (HRV) for physician-determined use which can assess autonomic nervous system dysfunction in diabetics.

And be used specifically in patients undergoing cardiovascular disease testing.

Potential Market PD2i Analyzer The potential market for the PD2i Analyzer with 77 million potential patients could be in the multi-billions of dollars. This market is supported by the recent FDA approval to market the PD2i Analyzer for cardiovascular disease testing is anticipated to spur market acceptance of the PD2i Analyzer as a valuable new diagnostic.

The groundbreaking 510(k) obtained in April of 2011, for the use of the PD2i metric includes the classical Ewing maneuvers with the PD2i metric in patients undergoing cardiovascular disease testing.

This FDA Approval is an accomplishment of incredible significance for VCRT as both national and international acceptance begin to accelerate. This landmark approval has been sought since the first introduction of the PD2i technology by Vicor in 2003.

These populations are significant:

23.6 million diabetics 15 million at-risk cardiac patients 38 million trauma incidents PD2i Analyzer Provides Additional Revenue Source for Physicians and Improves Patient Care Physicians can now expect a higher return on investment with the April 2011 FDA 501(k) for cardiovascular disease testing.

Vicor is now able to broaden its marketing message and could significantly increase interest in the Analyzer particularly with cardiologists.

Physicians are able to use the Analyzer for indications believed to be useful. FDA clearance of specific indications allows Vicor to explicitly market for those indications.

Current procedural terminology (CPT) codes enable physicians using the PD2i Analyzer to be reimbursed by insurance carriers, creating a recurring source of revenue from test analysis for Vicor.

The PD2i Analyzer is used as a diagnostic for heart rate variability, which is a widely-accepted measure of autonomic nervous system health and by extension cardiac health.

The PD2i Algorithm facilitates the ability of physicians to accurately risk stratify a specific target population to predict future pathological events such as autonomic nervous system dysfunction, cardiac mortality (either from arrhythmic death or congestive heart failure) and imminent death from trauma.

PD2i Algorithm New and Accurate Vital Sign The Company believes that the PD2i Algorithm represents a noninvasive monitoring technology that physicians and other members of the medical community can use as a new and accurate vital sign.

Two proprietary diagnostic medical products are being commercialized which employ software utilizing the PD2i Algorithm:

First – the PD2i Analyzer Second – the PD2i Cardiac Analyzer The PD2i VS Vital Sign Monitor for trauma, triage, and other hospital uses in still under development.

FDA Clearance In April 2011 the Company received 510(k) clearance from the U.S. Food and Drug Administration for its PD2i nonlinear algorithm and software to be used as a measure of heart rate variability at rest and in response to controlled exercise and paced respiration (Ewing Maneuvers) in patients specifically undergoing cardiovascular disease testing.

Physician use of the PD2i Analyzer is supported by an expanding body of literature demonstrating the value of the PD2i nonlinear algorithm as a metric for risk stratifying specific target populations for future pathological events.

This is the condensed version – Full StockGuru Profile Found Here:

http://www.sgurunews.com/emailmarketer/link.phpM596&N57&L69&F=T Contact Vicor Technologies, Inc.

David H. Fater, CEO Vicor Technologies, Inc.

561.995.7313 dfater@vicortech.com ..

a Vicor Technologies North Bay Resources VIASPACE, Inc.

Vuzix Corporation Mantra Venture Group Princeton Security Technologies Next 1 Interactive AtheroNovaAbout StockGuru:

The original service that has become StockGuru started in the late `90`s.

At first if was our publisher sharing picks with his friends. Then it grew.

Then it became a formal list in 2001. In 2002 it became a web site. In 2003 it became StockGuru. READ ALL ABOUT IT HERE.

..

Contact StockGuru:

P: 469-358-5200 F: 214-975-1238 Publisher@StockGuru.com This message was intended for “ You have received this message because you are subscribed to `Bold Stocks Alerts` VCRT Disclosure: Pentony Enterprises LLC entered into an investor relations consulting and market awareness contract with VCRT. We are also doing a video on ShareholderVision.com that will be released shortly. The Company will pay us a total of seventy two hundred dollars and fifty thousand shares of restricted 144 stock for the period ending August 31, 2011. We still hold hold these shares. To avoid all potential conflicts of interest, we never sell shares into the open market during an active market awareness or investor relations program. This means that as we release new information about a particular client company either on our site or otherwise authored by us, you can be confident we are not selling shares at the same time. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In early 2010, the Company paid us seventy two hundred dollars and fifty thousand shares of restricted 144 stock for a prior round of coverage that ended. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. Pentony Enterprises LLC 1601 Berwick Drive McKinney, Texas 75070 (469) 252-3031.

VCRT

Your email client cannot read this email.

To view it online, please go here:

http://www.sgurunews.com/emailmarketer/display.phpM596&C=c7c822f09eefcb0dac0453b7afd60b76&S49&L=3&N79 Shareholder Vision Releases New Video Interview with David Fater of Vicor Technologies, Inc.

Having trouble reading this email View it in your browser.

a Vicor Technologies, Inc.

Shareholder Vision Releases New Video Interview with David Fater of Vicor Technologies, Inc.

June 21, 2011 Dallas, Texas: John Pentony, Publisher of ShareholderVision.com, announced today that Shareholder Vision has released a new video interview featuring David Fater, President and Chief Executive Officer of Vicor Technologies, Inc. (OTCBB: VCRT). The interview was recorded recently in Boca Raton, Florida, the headquarters for Vicor Technologies, Inc. Shareholder Vision presents an exceptional look at an outstanding company, a CEO with world class experience in his field, and a bio-tech company that is now capitalizing on over a decade of patented work.

Vicor Technologies is a biotechnology company focused on the commercialization of its PD2i Analyzer, an innovative, non-invasive diagnostic employing its patented, proprietary PD2i nonlinear algorithm.

Physician use of the PD2i Analyzer is supported by an expanding body of literature documenting the PD2i nonlinear algorithm as a metric for risk stratifying specific target populations for future pathological events, including diabetics for the presence of diabetic autonomic neuropathy (DAN), cardiovascular disease patients for death resulting from arrhythmia or congestive heart failure, and trauma victims for imminent death absent immediate lifesaving intervention.

Vicor is actively transforming itself from a development-stage biotechnology company into a fully-realized commercial venture with a national sales force and international distribution. Physicians are using Vicors PD2i Analyzer to identify autonomic nervous system, also known as diabetic autonomic neuropathy (DAN), in their patients with diabetes, and to identify those among their patients with cardiovascular disease at risk for death resulting from arrhythmia or congestive heart failure.

Current procedural terminology (CPT) codes enable physicians using the PD2i Analyzer as a measure of heart rate variability to be reimbursed by insurance carriers, creating a recurring source of revenue from test analysis for Vicor. In April, Vicor received 510(k) marketing clearance from the U.S. Food and Drug Administration for its PD2i Analyzer to be used as a measure of heart rate variability at rest, and in response to controlled exercise and paced respiration (Ewing Maneuvers) in patients specifically undergoing cardiovascular disease testing.

Sixty published manuscripts of studies involving the use of Vicors PD2i nonlinear algorithm attest to its ability to identify and predict a wide variety of medical disorders and conditions.

To view the video interview, please visit:

http://www.sgurunews.com/emailmarketer/link.phpM596&N49&L00&F=T Vicor Technologies, Inc. (OTCBB: VCRT) Disclosure: Pentony Enterprises LLC entered into an investor relations consulting and market awareness contract with VCRT. We are also doing a video on ShareholderVision.com that will be released shortly. The Company will pay us a total of seventy two hundred dollars and fifty thousand shares of restricted 144 stock for the period ending August 31, 2011. We still hold hold these shares. To avoid all potential conflicts of interest, we never sell shares into the open market during an active market awareness or investor relations program. This means that as we release new information about a particular client company either on our site or otherwise authored by us, you can be confident we are not selling shares at the same time. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In early 2010, the Company paid us seventy two hundred dollars and fifty thousand shares of restricted 144 stock for a prior round of coverage that ended. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. Pentony Enterprises LLC 1601 Berwick Drive McKinney, Texas 75070 (469) 252-3031.

Contact:

Shareholder Vision John Pentony, Publisher john@shareholdervision.com Tel: (469) 250-3030 StockGuru`s Profile for Vicor Technologies, Inc.

This is the condensed version – Full StockGuru Profile Found Here:

http://www.sgurunews.com/emailmarketer/link.phpM596&N49&L69&F=T Vicor Technologies, Inc. (OTCBB: VCRT) is a medical diagnostics company focused on commercializing noninvasive diagnostic technology products based on its patented, proprietary point correlation dimension algorithm the PD2i Algorithm and software.

With the second FDA approval under its belt in April, Vicor is fully in the process of transforming itself into a commercial company with a national sales force and international reach.

The Company has all of the regulatory approvals in place already with regards to PD2i to generate substantial revenues.

FDA Approval of PD2i Analyzer for BOTH Heart Rate Variability and Cardiovascular Disease Testing Vicors PD2i Analyzer has FDA 510(k) marketing clearance to both:

Measure heart rate variability (HRV) for physician-determined use which can assess autonomic nervous system dysfunction in diabetics.

And be used specifically in patients undergoing cardiovascular disease testing.

Potential Market PD2i Analyzer The potential market for the PD2i Analyzer with 77 million potential patients could be in the multi-billions of dollars. This market is supported by the recent FDA approval to market the PD2i Analyzer for cardiovascular disease testing is anticipated to spur market acceptance of the PD2i Analyzer as a valuable new diagnostic.

The groundbreaking 510(k) obtained in April of 2011, for the use of the PD2i metric includes the classical Ewing maneuvers with the PD2i metric in patients undergoing cardiovascular disease testing.

This FDA Approval is an accomplishment of incredible significance for VCRT as both national and international acceptance begin to accelerate. This landmark approval has been sought since the first introduction of the PD2i technology by Vicor in 2003.

These populations are significant:

23.6 million diabetics 15 million at-risk cardiac patients 38 million trauma incidents PD2i Analyzer Provides Additional Revenue Source for Physicians and Improves Patient Care Physicians can now expect a higher return on investment with the April 2011 FDA 501(k) for cardiovascular disease testing.

Vicor is now able to broaden its marketing message and could significantly increase interest in the Analyzer particularly with cardiologists.

Physicians are able to use the Analyzer for indications believed to be useful. FDA clearance of specific indications allows Vicor to explicitly market for those indications.

Current procedural terminology (CPT) codes enable physicians using the PD2i Analyzer to be reimbursed by insurance carriers, creating a recurring source of revenue from test analysis for Vicor.

The PD2i Analyzer is used as a diagnostic for heart rate variability, which is a widely-accepted measure of autonomic nervous system health and by extension cardiac health.

The PD2i Algorithm facilitates the ability of physicians to accurately risk stratify a specific target population to predict future pathological events such as autonomic nervous system dysfunction, cardiac mortality (either from arrhythmic death or congestive heart failure) and imminent death from trauma.

PD2i Algorithm New and Accurate Vital Sign The Company believes that the PD2i Algorithm represents a noninvasive monitoring technology that physicians and other members of the medical community can use as a new and accurate vital sign.

Two proprietary diagnostic medical products are being commercialized which employ software utilizing the PD2i Algorithm:

First – the PD2i Analyzer Second – the PD2i Cardiac Analyzer The PD2i VS Vital Sign Monitor for trauma, triage, and other hospital uses in still under development.

FDA Clearance In April 2011 the Company received 510(k) clearance from the U.S. Food and Drug Administration for its PD2i nonlinear algorithm and software to be used as a measure of heart rate variability at rest and in response to controlled exercise and paced respiration (Ewing Maneuvers) in patients specifically undergoing cardiovascular disease testing.

Physician use of the PD2i Analyzer is supported by an expanding body of literature demonstrating the value of the PD2i nonlinear algorithm as a metric for risk stratifying specific target populations for future pathological events.

This is the condensed version – Full StockGuru Profile Found Here:

http://www.sgurunews.com/emailmarketer/link.phpM596&N49&L69&F=T Contact Vicor Technologies, Inc.

David H. Fater, CEO Vicor Technologies, Inc.

561.995.7313 dfater@vicortech.com ..

a Vicor Technologies North Bay Resources VIASPACE, Inc.

Vuzix Corporation Mantra Venture Group Princeton Security Technologies Next 1 Interactive AtheroNovaAbout StockGuru:

The original service that has become StockGuru started in the late `90`s.

At first if was our publisher sharing picks with his friends. Then it grew.

Then it became a formal list in 2001. In 2002 it became a web site. In 2003 it became StockGuru. READ ALL ABOUT IT HERE.

..

Contact StockGuru:

P: 469-358-5200 F: 214-975-1238 Publisher@StockGuru.com This message was intended for “ You have received this message because you are subscribed to `Bold Stocks Alerts` VCRT Disclosure: Pentony Enterprises LLC entered into an investor relations consulting and market awareness contract with VCRT. We are also doing a video on ShareholderVision.com that will be released shortly. The Company will pay us a total of seventy two hundred dollars and fifty thousand shares of restricted 144 stock for the period ending August 31, 2011. We still hold hold these shares. To avoid all potential conflicts of interest, we never sell shares into the open market during an active market awareness or investor relations program. This means that as we release new information about a particular client company either on our site or otherwise authored by us, you can be confident we are not selling shares at the same time. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In early 2010, the Company paid us seventy two hundred dollars and fifty thousand shares of restricted 144 stock for a prior round of coverage that ended. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. Pentony Enterprises LLC 1601 Berwick Drive McKinney, Texas 75070 (469) 252-3031.

VCRT

Share This Alert with Traders You Know! BOLD STOCKS BREAK-OUT ALERT: ALZM Allezoe Breaks Out, Hitting $1.95 on 4.5 Million Shares Traded Allezoe, Inc. (OTCBB: ALZM) Most Recent News for ALZM Allezoe (ALZM): OTS and Research Collaborators to Attend and Present at International Society for Heart and Lung Transplantation (ISHLT) FRISCO, TEXAS, Apr 04, 2011 (MARKETWIRE via COMTEX) — Allezoe (OTCBB:

ALZM) announces that members of the Organ Transport Systems (“OTS”) leadership team will attend the annual meeting of the International Society for Heart and Lung Transplantation (ISHLT) April 13-16, 2011 in San Diego, California, where OTS collaborators will be presenting results from their latest preclinical studies. OTS plans to redefine human organ transplantation with its LifeCradle(R) device through better preservation and ease of use of the LifeCradle(R) in the current donor organ procurement process, at minimal costs. The preclinical research performed by the OTS collaborators further substantiates these plans.

The International Society for Heart and Lung Transplantation (ISHLT) meeting and scientific sessions are held annually to gather the most prominent thoracic surgeons, physicians, research scientist, engineers, and others involved in heart and lung transplantation to share their most recent findings for best practices and to review any new, emerging technologies with their peers from around the world.

This year, the cardiothoracic research team from University of Texas Southwestern Medical Center in Dallas, led by Dr. Michael E. Jessen, Professor & Chairman of the Dept. of Cardiothoracic Surgery, will be presenting, `Retrograde Coronary Sinus Perfusion: An alternate approach for machine perfusion preservation of donor hearts for transplantation` authored by ML Cobert, LM West, ME Jessen, and M Peltz. Dr. Peltz will be presenting the paper at the ISHLT conference in San Diego. The study, which utilized an OTS LifeCradle(R) prototype, showed that the two preferred routes for perfusing the heart tissue in a transplant procedure both provided adequate oxygen and nutrients to maintain metabolism. Controlling the temperature so the hearts do not get too cold, as is the case when they are preserved on ice (the current standard method), and maintaining metabolism, prevents tissue damage during the preservation period and potentially gives the transplant team a more viable organ for the recipient.

Over the past several years OTS research collaborators have presented their pre-clinical research findings using the LifeCradle(R) HR donor heart preservation device at the ISHLT meetings showing that donor hearts can be better preserved by providing oxygen and nutrients to the heart tissue rather than just storing them on ice until they can be transplanted. This could potentially extend the preservation period and provide more time for delivery to recipients at greater distances. Currently, almost 10% of viable donated hearts are discarded because of time/geographical constraints, i.e. the donor hearts cannot be procured, transported, and then transplanted in the short 3-4 hours desirable for best outcomes.

During the ISHLT conference, Dr. Thomas D. Franklin, Jr., PhD, EVP of Research & Regulatory Affairs at OTS, will be meeting with members of OTS`s Medical Advisory Board and its Clinical Trial Steering Committee that have been reviewing and guiding the OTS research and clinical plans over the past several years. The meetings will allow OTS`s advisors to review the proposed clinical trial protocols and discuss ongoing research projects.

OTS announced last week that it had received initial funding to continue preparations for clinical trials of its LifeCradle(R) device.

For more details please visit the OTS website at www.organtransportsystems.com or the ISHLT website at www.ishlt.org.

About Allezoe (ALZM) Allezoe Medical Holdings, Inc. (ALZM) is the holding company for Organ Transport Systems, Inc. (“OTS”) and for future acquisitions targeted to medical products, solutions and services. We believe it is possible to create value for shareholders as well as recipients of healthcare services at the same time, and we do so by seeking out the highest quality medical devices. OTS, headquartered in Frisco, Texas, is a biomedical company engaged in developing, patenting, and commercializing portable hypothermic, oxygenated preservation and transport technology for human organs. OTS plans to redefine human organ transplantation through better preservation with its LifeCradle(R) product line.

FORWARD LOOKING STATEMENT This announcement is not an offer to sell any Allezoe (“ALZM”) related securities. Offers for any given security are made only through applicable offering circulars and related documents filed with the SEC pursuant to the Securities Act of 1933 or the Securities Exchange Act of 1934. Certain statements contained herein and subsequent oral statements made by and on behalf of ALZM may contain “forward looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward looking statements are identified by words such as “intends”, “anticipates”, “believes”, “expects”, and “hopes” and includes, without limitation, statements regarding ALZM`s plan of business operations, product research and development activities, anticipated revenues and expenses and potential contractual arrangements and obligations. Also, our management may make forward-looking statements orally to investors, analysts, the media and others. Forward-looking statements express our expectations or predictions of future events or results. They are not guarantees and are subject to many risks and uncertainties. There are a number of factors beyond our control that could cause actual events or results to be significantly different from those described in the forward-looking statements. Any or all of our forward-looking statements in this report or in any other public statements we make may turn out to be wrong. We undertake no obligation to publicly update or review any forward-looking statements, whether as a result of new information, future developments or otherwise.

Contacts:

Allezoe Medical Holdings, Inc.

Media Department 214-290-8031 media@allezoe.com www.allezoe.com ..

Get BOLD STOCKS on TWITTER:

http://www.sgurunews.com/emailmarketer/link.phpM596&N15&L8&F=T Get The BOLD STOCKS RSS FEED:

http://www.sgurunews.com/emailmarketer/link.phpM596&N15&L1&F=T ALZM Disclosure: Pentony Enterprises LLC has been retained as a consultant by a non-controlling third party. To avoid all potential conflicts of interest, we never sell shares into the open market during an active market awareness or investor relations program. This means that as we release new information about a particular client company either on our site or otherwise authored by us, you can be confident we are not selling shares at the same time. We hold no shares and will not be receiving further compensation in shares or that is share related during this period. Our total compensation is ten thousand dollars. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk – Pentony Enterprises LLC is BoldStocks.com- 1601 Berwick Drive | McKinney, Texas 75070 | 469-252-3030.

ALZM · ISHLT

Share This Alert with Traders You Know! BOLD STOCKS BREAK-OUT ALERT:

Trade Alert ALZM: Allezoe Medical Holdings, Inc. (OTCBB: ALZM) – Substantial Discount to Recent Highs May be Strong Buying Opportunity Dear Members, I know that anyone that is as much in to smallcap stocks as I am is closely monitoring Allezoe (OTCBB: ALZM). Over that past month ALZM has traded over 80 million shares, with prices as high as $2.60 a share. With Wednesday`s close of just $1.88, there could be a very significant buying opportunity. That price is a 27% discount off recnet highs achieved just six trading days prior.

Let`s first look at the fundamenals of ALZM:

Allezoe Medical Holdings, Inc. (OTCBB: ALZM) is the sole shareholder of Organ Transport Systems, Inc. which is focused on the development and commercialization of its LifeCradle(R) organ preservation technology.

Organ Transport has been in existence for nearly 12 years, has had more than $10 million invested in it over the years in the research and development for LifeCradle(R) technology.

Pre-clinical Experiments “Significantly Extend Useful Life of Hearts” In the pre-clinical experiments, researchers have concluded that the LifeCradle(R) significantly extends the useful life of hearts and provides a healthier heart after similar time periods of preservation compared to the current standard of care of heart preservation i.e. static, cold storage in “a picnic cooler” on ice.

Raising Funds for Final FDA Clinical Trials ALZM reported that on March 31, 2011, it received an initial investment to continue preparing its Life Cradle(R) technology for clinical trials.

According to Michael Holder, Chairman and CEO of Allezoe, “This initial investment will allow us to further our clinical trial preparations and provides bridge financing while we are negotiating a larger capital infusion from institutional investors to support the trials.” The Company is now working to raise additional capital from private sources to fund the final FDA clinical trials to bring the LifeCradle(R) to market.

LifeCradle(R) Tested LifeCradle(R) has been tested in more than 225 animal heart preservation experiments as well as over 15 discarded human heart experiments, leading to peer reviewed and published articles in the Journal of Transplantation and the Journal of Heart and Lung Transplantation as well as presentations by the OTS research collaborators at national and international meetings like the International Society for Heart and Lung Transplantation Conferences and the American Association of Thoracic Surgery.

More to come on ALZM… We will be watching this one very closely.

Forward Looking Statement: This is not an offer to sell any Allezoe (“ALZM”) related securities. Offers for any given security are made only through applicable offering circulars and related documents filed with the SEC pursuant to the Securities Act of 1933 or the Securities Exchange Act of 1934. Certain statements contained herein and subsequent oral statements made by and on behalf of ALZM may contain “forward looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.

Such forward looking statements are identified by words such as “intends”, “anticipates”, “believes”, “expects”, and “hopes” and includes, without limitation, statements regarding ALZM`s plan of business operations, product research and development activities, anticipated revenues and expenses and potential contractual arrangements and obligations. Also, our management may make forward-looking statements orally to investors, analysts, the media and others. Forward-looking statements express our expectations or predictions of future events or results. They are not guarantees and are subject to many risks and uncertainties. There are a number of factors beyond our control that could cause actual events or results to be significantly different from those described in the forward-looking statements. Any or all of our forward-looking statements in this report or in any other public statements we make may turn out to be wrong. We undertake no obligation to publicly update or review any forward-looking statements, whether as a result of new information, future developments or otherwise.

AHRO Disclosure: Pentony Enterprises LLC has been retained as a consultant by a non-controlling third party. To avoid all potential conflicts of interest, we never sell shares into the open market during an active market awareness or investor relations program. This means that as we release new information about a particular client company either on our site or otherwise authored by us, you can be confident we are not selling shares at the same time. We hold no shares and will not be receiving further compensation in shares or that is share related during this period. Our total compensation is ten thousand dollars. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.

Most Recent News for ALZM Allezoe (ALZM): OTS and Research Collaborators to Attend and Present at International Society for Heart and Lung Transplantation (ISHLT) FRISCO, TEXAS, Apr 04, 2011 (MARKETWIRE via COMTEX) — Allezoe (OTCBB:

ALZM) announces that members of the Organ Transport Systems (“OTS”) leadership team will attend the annual meeting of the International Society for Heart and Lung Transplantation (ISHLT) April 13-16, 2011 in San Diego, California, where OTS collaborators will be presenting results from their latest preclinical studies. OTS plans to redefine human organ transplantation with its LifeCradle(R) device through better preservation and ease of use of the LifeCradle(R) in the current donor organ procurement process, at minimal costs. The preclinical research performed by the OTS collaborators further substantiates these plans.

The International Society for Heart and Lung Transplantation (ISHLT) meeting and scientific sessions are held annually to gather the most prominent thoracic surgeons, physicians, research scientist, engineers, and others involved in heart and lung transplantation to share their most recent findings for best practices and to review any new, emerging technologies with their peers from around the world.

This year, the cardiothoracic research team from University of Texas Southwestern Medical Center in Dallas, led by Dr. Michael E. Jessen, Professor & Chairman of the Dept. of Cardiothoracic Surgery, will be presenting, `Retrograde Coronary Sinus Perfusion: An alternate approach for machine perfusion preservation of donor hearts for transplantation` authored by ML Cobert, LM West, ME Jessen, and M Peltz. Dr. Peltz will be presenting the paper at the ISHLT conference in San Diego. The study, which utilized an OTS LifeCradle(R) prototype, showed that the two preferred routes for perfusing the heart tissue in a transplant procedure both provided adequate oxygen and nutrients to maintain metabolism. Controlling the temperature so the hearts do not get too cold, as is the case when they are preserved on ice (the current standard method), and maintaining metabolism, prevents tissue damage during the preservation period and potentially gives the transplant team a more viable organ for the recipient.

Over the past several years OTS research collaborators have presented their pre-clinical research findings using the LifeCradle(R) HR donor heart preservation device at the ISHLT meetings showing that donor hearts can be better preserved by providing oxygen and nutrients to the heart tissue rather than just storing them on ice until they can be transplanted. This could potentially extend the preservation period and provide more time for delivery to recipients at greater distances. Currently, almost 10% of viable donated hearts are discarded because of time/geographical constraints, i.e. the donor hearts cannot be procured, transported, and then transplanted in the short 3-4 hours desirable for best outcomes.

During the ISHLT conference, Dr. Thomas D. Franklin, Jr., PhD, EVP of Research & Regulatory Affairs at OTS, will be meeting with members of OTS`s Medical Advisory Board and its Clinical Trial Steering Committee that have been reviewing and guiding the OTS research and clinical plans over the past several years. The meetings will allow OTS`s advisors to review the proposed clinical trial protocols and discuss ongoing research projects.

OTS announced last week that it had received initial funding to continue preparations for clinical trials of its LifeCradle(R) device.

For more details please visit the OTS website at www.organtransportsystems.com or the ISHLT website at www.ishlt.org.

About Allezoe (ALZM) Allezoe Medical Holdings, Inc. (ALZM) is the holding company for Organ Transport Systems, Inc. (“OTS”) and for future acquisitions targeted to medical products, solutions and services. We believe it is possible to create value for shareholders as well as recipients of healthcare services at the same time, and we do so by seeking out the highest quality medical devices. OTS, headquartered in Frisco, Texas, is a biomedical company engaged in developing, patenting, and commercializing portable hypothermic, oxygenated preservation and transport technology for human organs. OTS plans to redefine human organ transplantation through better preservation with its LifeCradle(R) product line.

FORWARD LOOKING STATEMENT This announcement is not an offer to sell any Allezoe (“ALZM”) related securities. Offers for any given security are made only through applicable offering circulars and related documents filed with the SEC pursuant to the Securities Act of 1933 or the Securities Exchange Act of 1934. Certain statements contained herein and subsequent oral statements made by and on behalf of ALZM may contain “forward looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward looking statements are identified by words such as “intends”, “anticipates”, “believes”, “expects”, and “hopes” and includes, without limitation, statements regarding ALZM`s plan of business operations, product research and development activities, anticipated revenues and expenses and potential contractual arrangements and obligations. Also, our management may make forward-looking statements orally to investors, analysts, the media and others. Forward-looking statements express our expectations or predictions of future events or results. They are not guarantees and are subject to many risks and uncertainties. There are a number of factors beyond our control that could cause actual events or results to be significantly different from those described in the forward-looking statements. Any or all of our forward-looking statements in this report or in any other public statements we make may turn out to be wrong. We undertake no obligation to publicly update or review any forward-looking statements, whether as a result of new information, future developments or otherwise.

Contacts:

Allezoe Medical Holdings, Inc.

Media Department 214-290-8031 media@allezoe.com www.allezoe.com ..

Get BOLD STOCKS on TWITTER:

http://www.sgurunews.com/emailmarketer/link.phpM596&N10&L8&F=T Get The BOLD STOCKS RSS FEED:

http://www.sgurunews.com/emailmarketer/link.phpM596&N10&L1&F=T BALZM Disclosure: Pentony Enterprises LLC has been retained as a consultant by a non-controlling third party. To avoid all potential conflicts of interest, we never sell shares into the open market during an active market awareness or investor relations program. This means that as we release new information about a particular client company either on our site or otherwise authored by us, you can be confident we are not selling shares at the same time. We hold no shares and will not be receiving further compensation in shares or that is share related during this period.

Our total compensation is ten thousand dollars. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk – Pentony Enterprises LLC is BoldStocks.com- 1601 Berwick Drive | McKinney, Texas 75070 | 469-252-3030.

AHRO · ALZM · BALZM · ISHLT

Your email client cannot read this email.

To view it online, please go here:

http://www.sgurunews.com/emailmarketer/display.phpM596&C=c7c822f09eefcb0dac0453b7afd60b76&S02&L=3&N28 Why You Must Get In On The Next Mega Trend Now! It Could Make You 5 Times Richer By Summer…

Your First Rapid 510% On Genmed (GENM) Could Be In Your Hands In 100 Days Or Less… Then, You Could Make As Much As 989% Before Snow Flies! Andy Carpenter Carpenter Global Stock Advisory ACTION ALERT Genmed SYMBOL GENM Dear Micro-Cap Investor:

Today`s media machine doesn`t let investment sweet spots like this last for long. Outstanding opportunities, like the one you`re about to see, are ripe today… and devoured by hungry investors tomorrow.

And this one is sweet. It is the one you`ve been waiting for.

You could pocket your first 510% success in less than 100 days…

then watch as that could double by Christmas… a 10 bagger The Death Of Communism Has Created A Vast, Unprecedented Opportunity For Big-Picture Investors Who Know The Power Of Free Markets All you have to do is get out ahead of the newest MEGA TREND that`s developing in Europe`s drug sector. It is a big deal… one that gets bigger every day.

This is a fast-expanding market that was cracked wide open when much of Europe cast off the shackles of communism and embraced the American form of Capitalism.

And, one company I`ve discovered looks poised to claim a highly profitable corner of this quarter-trillion-dollar market.

The company is Genmed (GENM). It sells products in the booming generic-drugs market.

My Top Picks Tend To Explode…

Rapidly Jumping 289%… 576%… 669% Hello, my name is Andrew Carpenter, editor of the Carpenter Global Stock Advisory. Some people call me the maverick genius of the micro-cap market.

I am known for finding soon-to-be-hot companies just before they pop…this talent for finding hidden gems has led major global newspapers, such as The Wall Street Journal, USA Today and The Shanghai Security News to write huge profiles about me.

In fact, The Wall Street Journal said that I have an uncanny knack for discovering companies… that fly below the radar screens of most Wall Street analysts, and that I Dig up information on companies Wall Street can`t be bothered with. USA Today said that I… Predicted one stock winner after another.

So people pay attention when I announce a new discovery.

Many of them will read a new Special Report I have written about Genmed (GENM), which your can read for FREE today just below here.

Genmed (GENM) It Could Be Your Best Global Opportunity Of The Year You can access it for FREE as part of an introduction to my newsletter… but you`re under no obligation… I won`t even ask for you email address. FREE is free to me.

You see, I`ve been looking for a company in the super-hot European drug sector… in particular, not some old, tired dinosaur… rather, I sought a young company… one with start-up power… and the potential to deliver explosive gains.

GENMED fills that bill.

Genmed`s Supplier Has Increased Production 300% To Keep Up With GENM`s Demand The Special Report covers all Genmed`s tremendous upside…

its rip-roaring potential to dominate the generic drug sector.

In my Genmed Special Report you see…

-How the big players of old are suddenly at a disadvantage to young Genmed (GENM)…

-Why one of Genmed`s suppliers had to increase production by 300% just to keep up with orders…

-Why Holland and the Czech Republic could hold the key to your fortunes…

-Why a new agreement in England opens a 1,200-pharmacy, 500-hospital market…

-How this final wave of European privatization could multiply your money by nearly 10X by Christmas.

There Is A Massive Demand For Less Expensive Drugs…

Genmed Looks Set To Shoot At Least 510% By July 4, Because It`s Selling FDA Approved Generic Drugs In A Huge, Newly Deregulated Market So, let`s get you to the Special Report now… take moment of your time to discover what could be one of the most important companies in the newly booming European drug sector…

a company you could own today for pennies! And, thanks for your time today.

( http://www.sgurunews.com/emailmarketer/link.phpM596&N02&L07&F=T) Andrew Carpenter, Editor, The Carpenter Global Stock Advisory P.S. Please don`t lose sight of the fact that as generic drug sales are set to boom in Europe after years of being held in check, Genmed is lined up and ready to supply Europe with top selling generic drugs.

And, you can be there to capture all the potential what could be as much as 510% by this summer… and the possibility to see it double after that.

You`ll find it all here for FREE.

( http://www.sgurunews.com/emailmarketer/link.phpM596&N02&L07&F=T) IMPORTANT NOTICE AND DISCLAIMER: Andrew Carpenter`s (Endorser) track record was compiled from calculations derived from documentation of his Carpenter Global Stock Advisory (CGSA) newsletter. Said newsletter and documentation were made available to CGSA subscribers. No representation is made that actual purchases and sales were made at the prices stated.

Facts stated in this article were supplied to endorser from third-party sources. Endorser makes no representations as to such facts` reliability, accuracy or completeness. Endorser is not responsible for errors or omissions.

Endorser does not claim any special expertise or knowledge regarding the European generic or pharmaceutical drug sector or of its OTC drug sector. Endorser is neither acting as an investment advisor nor providing individual investment advice. Andrew Carpenter and The Carpenter Global Stock Advisory OWN NO SHARES, OPTIONS, WARRANTS in Genmed Holding Corp. (GENM), Also, GENM neither approved nor paid for this specific advertisement. Readers should perform their own due diligence. The information presented is provided for information purposes only and the endorsement is not to be used or considered as an offer or the solicitation of an offer to sell or to buy or subscribe for securities.

Endorser has not taken any steps to ensure that the securities referred to in this report are suitable for any particular investor. Any securities referenced by Endorser may not be suitable for you and it is recommended that you consult an independent investment advisor if you are in doubt about such investments. Nothing in the endorsement constitutes investment, legal, accounting or tax advice or a representation that any investment or strategy is suitable or appropriate to your individual circumstances or otherwise constitutes a personal recommendation to you. Information, opinions and estimates referenced in the endorsement reflect a judgment at its original date of publication and are subject to change without notice.

The price and value of the securities mentioned in the endorsement can fall as well as rise, and may have a high level of volatility. High volatility securities may experience sudden and large falls in their value, leading to losses. High volatility investments may also be difficult to sell. Similarly, it may prove difficult for you to obtain reliable information about the value or risks to which such an investment is exposed. The endorsement may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the report refers to website material of Endorser, Endorser has not reviewed any recommended or linked site and takes no responsibility for the content contained therein. Such address or hyperlink is provided solely for your convenience and information and the content of the linked site does not in any way form part of the endorsement. Accessing such websites or following any link shall be at your own risk. Further, you are advised to read and carefully consider the additional explanations of risk factors in Genmed Holding Corp`s SEC filings that can be found online in the SEC`s EDGAR database at www.SEC.gov. Neither Andrew Carpenter nor his publication is offering securities for sale. Carpenter has been contracted to receive five thousand dollars by a third party, Wellington Manner LLC, for coverage of Genmed Holding Corp. In addition, the Carpenter Global Stock Advisory expects to receive new subscriber revenue as a result of this advertising effort. Finally, Penny Stocks are EXTREMELY RISKY.

You should consult with your registered investment adviser before investing to determine suitability and risk tolerance. Andrew Carpenter and The Carpenter Global Stock Advisory assume no risk for investor losses or profits. The information contained herein contains forward-looking information within the meaning of section 27a of the Securities Act of 1993, as amended, and section 21e of the Securities Exchange Act of 1934, as amended, including statements regarding expected growth of the featured company. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act, statements contained herein that look forward in time, which include everything other than historical information, involve risks and uncertainties that may affect the Genmed Holding`s actual results of operations. Factors that could cause actual results to differ include size and growth of the market, the Company`s ability to fund its capital requirements in the near term and in the long term; pricing pressures, technology issues etc.

There is no guarantee that past results are indicative of future performance.

Compensation and Other Disclosures The content of this message is published by Genmed Holding Corp and sent to select email lists through Lake Group Media, Inc. (“Lake”) to provide readers with information on selected publicly traded companies. Factual information is obtained from public filings and other sources deemed to be reliable; however, neither Genmed Holding Corp nor Lake takes responsibility for verifying the accuracy of such information and they make no representation that such information is accurate or complete. Certain of the statements in this Update may be considered forwarded looking statements. Genmed Holding Corp and Lake make no representation and provide no assurance or guaranty that such forward looking statements will prove to be accurate. See the companies filings with the Securities and Exchange Commission for factors that may cause results to be significantly different. Statements of opinion and belief are those of the authors and/or editors of this Update, and are based solely upon the information possessed by such authors and/or editors; no inference should be drawn that such authors or editors have any special or greater knowledge about the company or companies profiled or any particular expertise in the industries or markets in which the profiled company or companies compete. The reader should verify all claims and complete his own due diligence before investing in any securities of the profiled company or companies.

Neither Genmed Holding Corp, Lake, nor anyone involved in the publication or dissemination of this Update is a registered investment adviser or broker/dealer. Genmed Holding Corp and Lake make no recommendation that the purchase of securities of the company or companies profiled in this Update are suitable or advisable for any person or that an investment in such securities will be profitable. In general, given the nature of the company or companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree! of risk. An investor in such securities should be prepared and able t o bear a loss of his or her entire investment. Nothing in this Update should be construed as an offer or solicitation to buy or sell any securities of any profiled company. Lake has been retained to provide direct marketing services for the company profiled in this Update and receives compensation for those services.

Further, Lake and its employees and affiliates may own, or may purchase and sell, securities of the company or companies profiled. Lake undertakes no obligation to inform readers about the ownership or trading activities of it or its employees or affiliates in the securities of the profiled company or companies. Lake has the following compensation arrangements with the company or companies profiled in this Update: Lake receives an advertising fee ranging from $1,000 to $100,000 for each direct marketing list recommended and ordered for the dissemination of this Update.

Paid Advertising – Pentony Enterprises LLC “PE” The report and content of this presentation is a paid advertisement. It was paid for by a non-controlling third party for dissemination of this copy. We have taken no shares. To avoid all potential conflicts of interest, we never sell shares into the open market during an active market awareness or investor relations program. This means that as we release new information about a particular client company either on our site or otherwise authored by us, you can be confident we are not selling shares at the same time. We hold no shares and will not be receiving further compensation in shares or that is share related during this period. Total compensation from the third party for sending this and other advertising copy associated with GENM totals no more than three thousand three hundred dollars. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. As advertising, PE was hired for the distribution of the attached content. PE did not author or endorse the content, and as a rule never does when hired for advertising. Paid Advertising – Pentony Enterprises LLC 1601 Berwick Drive McKinney, Texas 75070 (469) 252-3031.

To stop receiving these emails:http://www.sgurunews.com/emailmarketer/

CGSA · GENM · RISKY